Synthesis of process related Dapsone impurities : Selective diazotization of aromatic di-amine

Author(s)
Mahesh Bandishti, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India
Balaji Chaugule, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India
Chinmoy Pramanik, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India
Ganesh Karhade, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India
Ashok Chaudhari, API R&D Centre, Emcure Pharmaceuticals Ltd., ITBT Park, Phase-II, MIDC, Hinjewadi, Pune-411057, India

Abstract
Process related two impurities of Dapsone were synthesized by applying cu-catalyzed conversions for the impurity profile and toxicological study. Controlled mono-diazotization of Dapsone followed by insitu iodination is the key step of our synthesis.

Keywords
Non-aqueous diazotization, Ullmann reactions, Process related impurities, Impurity Profile, Isoamyl nitrite and Hydroxylation.

Cite this paper
Mahesh Bandishti, Balaji Chaugule, Chinmoy Pramanik, Ganesh Karhade, Ashok Chaudhari, Synthesis of process related Dapsone impurities : Selective diazotization of aromatic di-amine, SCIREA Journal of Chemistry. Vol. 7 , No. 2 , 2022 , pp. 33 - 41 . https://doi.org/10.54647/chemistry15253

References

[ 1 ]	Oelschlaeger H, Modrack H, (1986) Arch Der Pharm 319 (1), 10.
[ 2 ]	Ritter C V, Grisham M B, Granger D N,(1989) Gastroenterology , 96, 811.
[ 3 ]	Rensburg C E, Van Gatner E M, Lmkamp F M, Anderson R,(1982) Antimicrob, Agents Chemother , 21(5), 693.
[ 4 ]	Johnson L A, Wirostko E, US Patent 4 220 657 (1978).
[ 5 ]	a. Allegrini P, Napoletano C, Razzetti G, Castaldi G and US 0192929, 2008. b. Roblin R O, Williams J H,U S Patent No. 2227400, 1941. c. Weijlard J, Messelry J P, U S Patent No 2385899, 1945. d.Villa M, Faveri C D, Zanotti R, Ciardella F, Borin F, US 0293970, 2008. e. Nariman A E, Maha A H, Samia A T, Ghada A S,(2021) Acta Chromatographica, f. Adrian L, Ulrike H, (2021) Journal of Pharamaceutcal and Biomedical Analysis ,198.
[ 6 ]	a. Go¨ro¨g S (2006) Trends in Analytical Chemistry, (25) 8, 755-757. b. Rao N R, Kiran S S M, Prasanthi N L, (2010), Indian J Pharm Educ Res 44(3), 301- 310.
[ 7 ]	a) ICH Guidelines, Q3A (R2), (2006) Impurities in New Drug Substances. b) ICH Guidelines, Q3B (R2), (2006) Impurities in New Drug Products. c) ICH Guidelines Q3C (R5), (2011) Guideline for residual solvents.
[ 8 ]	a. Gannett P M, Johnson E M, Grimes M A, Myers A L, Deavers R E, Tracy T S, (2003) Journal of Labelled Compounds and radiopharmaceuticals, 46(2), 107–114. b. Mannan C A, Krol G, Kho B T,(1977) J Pharm Sci , 66(11), 1618–1623. c. Cheung A P, Lim P,( 1977)J Pharm Sci , 66(12), 1723–1726. d. Gordon G R, Ghoul D C, Peters J H, (1975) J Pharm Sci , 64(7), 1205–1207.
[ 9 ]	a. Sandmeyer T, (1884) Ber Dtsch Chem Ges, 17 (3), 1633–1635. b. Sandmeyer T,(1884) Ber Dtsch Chem Ges, 17 (4), 2650–2653.
[ 10 ]	a. Ullmann F, Bielecki J, (1901)Ber Dtsch Chem Ges,34, 2174. b. Ullmann F,(1903) Ber Dtsch Chem Ges, 36, 2382. c. Ullmann F, Sponagel P, (1905)Ber Dtsch Chem Ges, 38, 2211
[ 11 ]	Evano G, Blanchard N, Toumi,(2008) M. Chem Rev, 108, 3054-3131.
[ 12 ]	Doyle M P, Bryker W J, (1979)J Org Chem, 44, 1572.
[ 13 ]	Chang J, Liu R, Zhu H, (2009) X-ray structure analysis, 25, 73.
[ 14 ]	Matsuda A, Shinozaki M, Yamaguchi T, Homma H, Nomoto R, Miyasaka T, Watanabe Y, Abiru T,(1992) J Med Chem 35, 241-252.
[ 15 ]	Zhao D, Wu N, Zhang S, Xi Su X, Lan J, You J,(2009) Angew Chem Int Ed , 48, 8729-8732
[ 16 ]	Chen G, Chan A S C, Kwong F Y ,(2007) Tetrahedron letter,48, 473-476.
[ 17 ]	a. Buck E, Song Z J, Tschaen D, Dormer P G, Volante R P, Reider P J, (2002),Org Lett 4(9), 1623-1626, b. Sawyer J S,(2000) Tetrahedron , 56, 5045, c. Theil F, Angew Chem , (1999) Int Ed, , 38, 2345. d. Lindley J. (1984) Tetrahedron 40, 1433.